

Comparative analysis of prostate-specific antigen free  
low, intermediate and high risk prostate cancer treatment  
the Prostate Cancer Results Study Group

BJU International

109, 22-29

DOI: [10.1111/j.1464-410x.2011.10827.x](https://doi.org/10.1111/j.1464-410x.2011.10827.x)

Citation Report

#	ARTICLE	IF	CITATIONS
4	APPLES AND ORANGES: COMPARISON OF TREATMENT METHODS FOR PROSTATE CANCER USING BIOCHEMICAL RECURRENCE AS AN ENDPOINT. <i>BJU International</i> , 2012, 110, E330-1.	1.3	2
6	Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. <i>BJU International</i> , 2012, 110, E431-2; author reply E432.	1.3	8
8	Educating our Patients Collaboratively: A Novel InterProfessional Approach. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2012, 43, 136.	0.2	0
10	Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. <i>Radiation Oncology</i> , 2012, 7, 209.	1.2	5
11	Current Status of Brachytherapy for Prostate Cancer. <i>Korean Journal of Urology</i> , 2012, 53, 743.	1.2	9
12	Educational Corner Prostate cancer brachytherapy: guidelines overview. <i>Journal of Contemporary Brachytherapy</i> , 2012, 2, 116-120.	0.4	19
13	MicroRNAs as putative mediators of treatment response in prostate cancer. <i>Nature Reviews Urology</i> , 2012, 9, 397-407.	1.9	36
14	Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint. <i>BJU International</i> , 2012, 110, 477-478.	1.3	6
15	Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants. <i>BJU International</i> , 2013, 111, 897-904.	1.3	4
16	Brachytherapy: Current Status and Future Strategies "Can High Dose Rate Replace Low Dose Rate and External Beam Radiotherapy?". <i>Clinical Oncology</i> , 2013, 25, 474-482.	0.6	76
17	Current standards and future directions for prostate cancer radiation therapy. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 75-88.	1.1	13
18	Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: a matched cohort analysis. <i>World Journal of Urology</i> , 2013, 31, 1511-1517.	1.2	13
20	Radical prostatectomy in high-risk prostate cancer. <i>International Journal of Urology</i> , 2013, 20, 290-300.	0.5	22
21	Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. <i>Radiotherapy and Oncology</i> , 2013, 109, 246-250.	0.3	9
22	DNA Ploidy Measured on Archived Pretreatment Biopsy Material May Correlate With Prostate-Specific Antigen Recurrence After Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 829-834.	0.4	8
24	MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 21414-21434.	1.8	42
26	Long-term Outcomes and Toxicity in Patients Treated With Brachytherapy for Prostate Adenocarcinoma Younger Than 60 Years of Age at Treatment With Minimum 10 Years of Follow-up. <i>Urology</i> , 2013, 81, 364-369.	0.5	31
27	Evolution of advanced technologies in prostate cancer radiotherapy. <i>Nature Reviews Urology</i> , 2013, 10, 565-579.	1.9	61

#	ARTICLE	IF	CITATIONS
28	MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer. <i>European Journal of Radiology</i> , 2013, 82, e775-e781.	1.2	19
29	Prostate-Specific Antigen Bounce After High-Dose-Rate Monotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 729-733.	0.4	24
30	A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e21-e28.	0.4	59
31	Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2013, 107, 372-376.	0.3	70
32	Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. <i>Brachytherapy</i> , 2013, 12, 628-636.	0.2	30
33	Radiation Therapy for Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 483-494.	0.6	1
34	Focal brachytherapy for selected low-risk prostate cancers: A pilot study. <i>Brachytherapy</i> , 2013, 12, 331-337.	0.2	89
35	Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones. <i>Brachytherapy</i> , 2013, 12, 608-614.	0.2	3
37	Salvage Cryosurgery of the Prostate for Failure After Primary Radiotherapy or Cryosurgery: Long-term Clinical, Functional, and Oncologic Outcomes in a Large Cohort at a Tertiary Referral Centre. <i>European Urology</i> , 2013, 64, 1-7.	0.9	80
38	Canadian Prostate Brachytherapy in 2012. <i>Canadian Urological Association Journal</i> , 2013, 7, 51.	0.3	19
39	Oncology training programs: are we doing comparative effectiveness research justice?. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 573-582.	0.6	0
40	High-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 349-354.	0.9	14
41	Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: a systematic review. <i>Canadian Urological Association Journal</i> , 2013, 7, 463.	0.3	20
42	Review article Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer between options. <i>Journal of Contemporary Brachytherapy</i> , 2013, 1, 33-41.	0.4	64
43	Racial and socioeconomic disparities in the selection of prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2013, 3, 139-143.	0.4	8
44	<i>TPRSS2-ERG</i> Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. <i>Clinical Cancer Research</i> , 2013, 19, 5202-5209.	3.2	39
45	Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low- and intermediate-risk prostate cancer. <i>Cancer</i> , 2013, 119, 1537-1546.	2.0	99
46	Defining a dose-response relationship for prostate external beam radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 237-246.	0.9	16

#	ARTICLE	IF	CITATIONS
47	Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. <i>Expert Review of Medical Devices</i> , 2013, 10, 751-763.	1.4	8
48	Biochemical Recurrence: A Valuable Endpoint?. <i>Medical Radiology</i> , 2013, , 55-64.	0.0	0
49	Focal Therapy and the Index Lesion Hypothesis in Prostate Cancer. <i>Medical Radiology</i> , 2013, , 173-183.	0.0	0
50	Change in the risk stratification of prostate cancer after Slide Review by a urologist: the experience of a reference center for the treatment of prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 454-462.	0.7	1
52	Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -. <i>Radiation Oncology</i> , 2014, 9, 302.	1.2	20
53	Permanent Seed Implantation. <i>Medical Radiology</i> , 2014, , 187-210.	0.0	0
54	Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 163-169.	2.0	31
55	Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. <i>BMJ, The</i> , 2014, 348, g1502-g1502.	3.0	204
56	Proton Therapy for Prostate Cancer: Technological and Clinical Aspects. <i>Medical Radiology</i> , 2014, , 263-275.	0.0	0
57	High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer. <i>Medical Radiology</i> , 2014, , 211-224.	0.0	0
58	Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 39-50.	1.1	14
59	The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. <i>Cancer</i> , 2014, 120, 2114-2121.	2.0	96
60	A Dose-Response Analysis of Biochemical Control Outcomes After 125I Monotherapy for Patients With Favorable-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1069-1075.	0.4	18
61	Modern Brachytherapy. <i>Seminars in Oncology</i> , 2014, 41, 831-847.	0.8	23
62	New recommendations in prostate cancer screening and treatment. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2014, 27, 14-20.	0.1	4
63	The status of surgery in the management of high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 342-351.	1.9	34
64	Hypofractionated External Beam Radiotherapy to Boost the Prostate with 85Gy/Equivalent Dose for Patients with Localised Disease at High Risk of Lymph Node Involvement: Feasibility, Tolerance and Outcome. <i>Clinical Oncology</i> , 2014, 26, 316-322.	0.6	13
65	Dosimetric Considerations to Determine the Optimal Technique for Localized Prostate Cancer Among External-Photon, Proton, or Carbon-Ion Therapy and High-Dose-Rate or Low-Dose-Rate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 715-722.	0.4	75

#	ARTICLE	IF	CITATIONS
66	Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. <i>World Journal of Urology</i> , 2014, 32, 1423-1432.	1.2	12
67	<scp>FROGG</scp> high-risk prostate cancer workshop: Patterns of practice and literature review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 257-265.	0.9	4
68	The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients. <i>International Journal of Clinical Oncology</i> , 2014, 19, 1080-1084.	1.0	1
69	Educating Our Patients Collaboratively: A Novel Interprofessional Approach. <i>Journal of Cancer Education</i> , 2014, 29, 382-388.	0.6	8
70	Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate brachytherapy within a provincial institution. <i>Brachytherapy</i> , 2014, 13, 46-52.	0.2	21
71	Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts. <i>Journal of Cellular Physiology</i> , 2014, 229, 1170-1176.	2.0	23
72	Prostate Cancer Genomics as a Driver of Personalized Medicine. , 2014, , 233-245.		1
73	Survey of high-dose-rate prostate brachytherapy practice in <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand, 2010-2011. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 101-108.	0.9	4
74	Results of a cohort of 200 hormone-naïve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team. <i>Cancer Radiotherapy: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014, 18, 643-648.	0.6	6
75	Advances in Androgen Receptor Targeted Therapy for Prostate Cancer. <i>Journal of Cellular Physiology</i> , 2014, 229, 271-276.	2.0	58
76	Late Urinary Side Effects 10 Years After Low-Dose-Rate Prostate Brachytherapy: Population-Based Results From a Multiphysician Practice Treating With a Standardized Protocol and Uniform Dosimetric Goals. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 570-578.	0.4	52
77	Promise and Pitfalls of Heavy-Particle Therapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 2855-2863.	0.8	105
78	Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life. <i>Radiotherapy and Oncology</i> , 2014, 112, 77-82.	0.3	85
79	Delivery systems for brachytherapy. <i>Journal of Controlled Release</i> , 2014, 192, 19-28.	4.8	16
80	Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife® treatment for prostate cancer – a case report. <i>Radiation Oncology</i> , 2014, 9, 186.	1.2	11
81	Salvage brachytherapy for recurrent prostate cancer. <i>Brachytherapy</i> , 2014, 13, 53-58.	0.2	41
82	A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. <i>Future Oncology</i> , 2014, 10, 457-474.	1.1	18
83	Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis. <i>World Journal of Surgical Oncology</i> , 2014, 12, 134.	0.8	5

#	ARTICLE	IF	CITATIONS
84	The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. <i>Radiation Oncology</i> , 2014, 9, 107.	1.2	21
85	Patterns of failure after iodine-125 seed implantation for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 68-71.	0.3	4
86	Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. <i>Clinical Oncology</i> , 2014, 26, 210-215.	0.6	17
87	Whole prostate D90 and V100: A dose-response analysis of 2000 consecutive 125I monotherapy patients. <i>Brachytherapy</i> , 2014, 13, 32-41.	0.2	32
89	Long-Term Results of Optimized Focal Therapy for Prostate Cancer: Average 10-Year Follow-Up in 70 Patients. <i>Journal of Men's Health</i> , 2014, 11, 64-74.	0.1	1
90	Brachytherapy: state-of-the-art radiotherapy in prostate cancer. <i>BJU International</i> , 2015, 116, 80-88.	1.3	20
91	High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy. <i>Oncology Research and Treatment</i> , 2015, 38, 639-644.	0.8	5
92	Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities. <i>International Journal of Oncology</i> , 2015, 46, 381-388.	1.4	6
94	Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study. <i>Radiation Oncology</i> , 2015, 10, 130.	1.2	6
95	Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study. <i>Radiation Oncology</i> , 2015, 10, 228.	1.2	17
96	Previous radiation for prostate neoplasm alters surgical and oncologic outcomes after rectal cancer surgery. <i>Journal of Surgical Oncology</i> , 2015, 112, 802-808.	0.8	8
97	Salvage helical tomotherapy for prostate cancer recurrence following definitive external beam radiotherapy: A case report. <i>Oncology Letters</i> , 2015, 10, 1044-1046.	0.8	2
98	Original paper Effect of a urinary catheter on seed position and rectal and bladder doses in CT-based post-implant dosimetry for prostate cancer brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2015, 3, 211-217.	0.4	1
99	Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy. <i>Korean Journal of Urology</i> , 2015, 56, 703.	1.2	4
100	Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1064-1070.	0.4	49
101	Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 509-514.	0.3	25
102	Cognitive factors influencing treatment decision-making in patients with localised prostate cancer: development of a standardised questionnaire. <i>Acta Clinica Belgica</i> , 2015, 70, 272-279.	0.5	5
103	Point: Surgery is the most cost-effective option for prostate cancer needing treatment. <i>Brachytherapy</i> , 2015, 14, 753-755.	0.2	0

#	ARTICLE	IF	CITATIONS
104	Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients. <i>Brachytherapy</i> , 2015, 14, 111-117.	0.2	41
105	Role of brachytherapy for advanced prostate cancer. <i>Current Problems in Cancer</i> , 2015, 39, 48-51.	1.0	1
106	The Case for Prostate Brachytherapy in the Affordable Care Act Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 465-467.	0.4	7
107	Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort. <i>Brachytherapy</i> , 2015, 14, 166-172.	0.2	17
108	A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 96-103.	2.0	19
109	Ten-year outcomes of I125 low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan. <i>World Journal of Urology</i> , 2015, 33, 1519-1526.	1.2	12
110	Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. <i>Brachytherapy</i> , 2015, 14, 316-321.	0.2	8
111	Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 350-358.	0.2	5
112	Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 334-341.	0.2	18
113	The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine-125 Seed Brachytherapy in Edinburgh. <i>Clinical Oncology</i> , 2015, 27, 519-526.	0.6	7
114	The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy. <i>Clinical Oncology</i> , 2015, 27, 382-386.	0.6	7
115	Optimised Robust Treatment Plans for Prostate Cancer Focal Brachytherapy. <i>Procedia Computer Science</i> , 2015, 51, 914-923.	1.2	15
116	Histogram analysis of diffusion kurtosis magnetic resonance imaging in differentiation of pathologic Gleason grade of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 337.e15-337.e24.	0.8	64
117	A new optimization method using a compressed sensing inspired solver for real-time LDR-brachytherapy treatment planning. <i>Physics in Medicine and Biology</i> , 2015, 60, 2179-2194.	1.6	14
118	Salvage cryosurgery for locally recurrent prostate cancer after primary cryotherapy. <i>International Urology and Nephrology</i> , 2015, 47, 301-305.	0.6	15
119	Organ-Confined Prostate Cancer: Are We Moving Towards More or Less Radical Surgical Intervention?. <i>Current Urology Reports</i> , 2015, 16, 27.	1.0	3
120	The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer. <i>Radiation Oncology</i> , 2015, 10, 60.	1.2	6
121	Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 862-867.	0.8	3

#	ARTICLE	IF	CITATIONS
122	Brachytherapy: Where Has It Gone?. <i>Journal of Clinical Oncology</i> , 2015, 33, 980-982.	0.8	102
123	Sector analysis provides additional spatial information on the permanent prostate brachytherapy learning curve. <i>Brachytherapy</i> , 2015, 14, 703-710.	0.2	2
124	Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: A comparison of Australian series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 125-133.	0.9	27
125	Imaging of Complications and Toxicity Following Tumour Therapy: Pelvis and Genitourinary (Male). <i>Medical Radiology</i> , 2015, , 195-214.	0.0	0
126	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 2345-2367.	1.3	81
127	Is robotic arm stereotactic body radiation therapy "virtual high-dose rate brachytherapy" effective for prostate cancer? An analysis of comparative effectiveness using published data. <i>Expert Review of Medical Devices</i> , 2015, 12, 317-327.	1.4	8
128	Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 141-149.	0.4	35
129	Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. <i>Osteoporosis International</i> , 2015, 26, 2281-2290.	1.3	26
130	DWI-associated entire-tumor histogram analysis for the differentiation of low-grade prostate cancer from intermediate-to-high-grade prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 3214-3221.	2.0	32
132	Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 303-309.	1.0	13
133	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 85-94.	0.8	107
134	Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. <i>Acta Oncologica</i> , 2015, 54, 875-881.	0.8	50
135	Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?. <i>Journal of Contemporary Brachytherapy</i> , 2016, 4, 289-293.	0.4	16
136	Comparative cost-effectiveness of focal and total salvage 125 I brachytherapy for recurrent prostate cancer after primary radiotherapy. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 484-491.	0.4	4
137	Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	44
138	Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. <i>Journal of Contemporary Brachytherapy</i> , 2016, 3, 165-172.	0.4	26
139	Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer. <i>Current Urology</i> , 2016, 9, 67-72.	0.4	7
140	Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer. <i>Medical Dosimetry</i> , 2016, 41, 236-241.	0.4	6



#	ARTICLE	IF	CITATIONS
141	Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 531-538.	0.9	11
142	Which patients benefit from post-implant CT dosimetry after real-time intraoperative planning for LDR prostate brachytherapy: Should intraoperatively planned patients be treated differently?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 244-246.	0.9	1
143	Real-time inverse high-dose-rate brachytherapy planning with catheter optimization by compressed sensing-inspired optimization strategies. <i>Physics in Medicine and Biology</i> , 2016, 61, 5956-5972.	1.6	8
144	The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 156-162.	0.2	3
145	Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1443-1453.	0.4	24
146	Impact of prostate catheter displacement in inverse planning—simulated annealing and geometric optimization. <i>Brachytherapy</i> , 2016, 15, 112-117.	0.2	1
147	Reply from Authors re: Tillmann Loch, Pat Fox Fulgham. Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow. <i>Eur Urol</i> 2016;69:1034-6. <i>European Urology</i> , 2016, 69, 1037.	0.9	0
148	Rectal Ulcers and Rectoprostatic Fistulas after <sup>125</sup> I Low Dose Rate Prostate Brachytherapy. <i>Journal of Urology</i> , 2016, 195, 1811-1816.	0.2	17
149	A radiobiology-based inverse treatment planning method for optimisation of permanent I-125 prostate implants in focal brachytherapy. <i>Physics in Medicine and Biology</i> , 2016, 61, 430-444.	1.6	16
150	Prostate cancer radiation therapy: A physician's perspective. <i>Physica Medica</i> , 2016, 32, 438-445.	0.4	22
151	Should Treatment with Radiation and Androgen Deprivation Therapy be Considered the "Gold Standard" for Men with Unfavourable Intermediate- to High-risk and Locally Advanced Prostate Cancer?. <i>Clinical Oncology</i> , 2016, 28, 475-478.	0.6	3
152	A comprehensive analysis of brachytherapy clinical trials over the past 15 years. <i>Brachytherapy</i> , 2016, 15, 679-686.	0.2	2
153	Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 624-628.	0.4	48
154	The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. <i>Brachytherapy</i> , 2016, 15, 701-706.	0.2	37
155	Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. <i>British Journal of Radiology</i> , 2016, 89, 20150981.	1.0	27
156	Prostate brachytherapy: Why do we ignore the evidence?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 528-530.	0.9	1
157	Epididymal Metastasis of Prostate Cancer Detected With <sup>68</sup> Ga-PSMA-PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 792-793.	0.7	7
158	Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2016, 15, 420-425.	0.2	7

#	ARTICLE	IF	CITATIONS
159	Is Surgery Still Necessary for Prostate Cancer?. , 2016, , 235-243.		0
160	Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 261-267.	0.6	28
161	Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 426-434.	0.2	26
162	Brachytherapy: a dying art or missed opportunity?. Australasian Physical and Engineering Sciences in Medicine, 2016, 39, 5-9.	1.4	4
163	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. Radiation Oncology, 2016, 11, 48.	1.2	12
164	Re-implantation following suboptimal dosimetry in low-dose-rate prostate brachytherapy: technique for outpatient source insertion using local anesthesia. Journal of Radiation Oncology, 2016, 5, 103-108.	0.7	0
166	Brachytherapy for Prostate Cancer: An Overview. , 2016, , 399-411.		0
167	High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. International Journal of Radiation Oncology Biology Physics, 2016, 94, 667-674.	0.4	101
168	Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e11-119.e18.	0.8	14
169	Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e19-119.e26.	0.8	25
170	Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer. International Journal of Clinical Oncology, 2016, 21, 595-600.	1.0	15
171	Technologies and Methods in Primary Ablation with Focal Therapy. , 2016, , 167-185.		0
172	What is the best way to radiate the prostate in 2016?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 59-68.	0.8	31
173	Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e342-e347.	0.7	14
174	Re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiblation Study of 111 Patients. Eur Urol 2017;71:267-73. European Urology, 2017, 72, e13-e14.	0.9	0
175	Permanent and High Dose Rate Brachytherapy (Technique, Indications, Results, Morbidity). , 2017, , 187-202.		1
176	Magnetic resonance imaging-guided functional anatomy approach to prostate brachytherapy. Brachytherapy, 2017, 16, 698-714.	0.2	10
177	Radiotherapy in the Management of Prostate Cancer. Medical Radiology, 2017, , 87-112.	0.0	0

#	ARTICLE	IF	CITATIONS
178	Beam distortion due to gold fiducial markers during salvage high-intensity focused ultrasound in the prostate. <i>Medical Physics</i> , 2017, 44, 679-693.	1.6	8
179	Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging. <i>Brachytherapy</i> , 2017, 16, 728-733.	0.2	4
180	American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy—A systematic literature review. <i>Brachytherapy</i> , 2017, 16, 245-265.	0.2	46
181	Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow. <i>Brachytherapy</i> , 2017, 16, 734-742.	0.2	29
182	Brachytherapy boost for prostate cancer: Trends in care and survival outcomes. <i>Brachytherapy</i> , 2017, 16, 330-341.	0.2	26
183	Use of magnetic resonance imaging in low-dose-rate and high-dose-rate prostate brachytherapy from diagnosis to treatment assessment: Defining the knowledge gaps, technical challenges, and barriers to implementation. <i>Brachytherapy</i> , 2017, 16, 672-678.	0.2	15
184	Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 378-382.	0.4	0
185	In the era of IGRT and small and focal field external beam radiotherapy, brachytherapy is a dying modality. <i>Medical Physics</i> , 2017, 44, 351-354.	1.6	0
186	Second malignancies after permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2017, 21, 210-215.	0.6	8
188	MRI Image-Guided Low-Dose Rate Brachytherapy for Prostate Cancer. , 2017, , 319-344.		3
189	Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models. <i>Medical Physics</i> , 2017, 44, 4329-4340.	1.6	6
190	Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 670-677.	3.3	58
191	Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. <i>Brachytherapy</i> , 2017, 16, 761-769.	0.2	9
192	Brachytherapy in the Management of Prostate Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 491-513.	0.6	17
193	ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 1-10.	0.6	10
194	Displacement patterns of stranded I-125 seeds after permanent brachytherapy of the prostate: Dosimetry in the operating room put into perspective. <i>Radiotherapy and Oncology</i> , 2017, 124, 68-73.	0.3	3
195	Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for 125 I prostate brachytherapy. <i>Brachytherapy</i> , 2017, 16, 282-290.	0.2	9
196	High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status. <i>Clinical Oncology</i> , 2017, 29, 401-411.	0.6	45

#	ARTICLE	IF	CITATIONS
197	Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. <i>Brachytherapy</i> , 2017, 16, 186-192.	0.2	20
198	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2017, 16, 266-276.	0.2	26
199	<sup>125</sup> I brachytherapy in younger prostate cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 707-713.	1.0	9
200	Quantification of large scale DNA organization for predicting prostate cancer recurrence. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 1164-1174.	1.1	10
202	The evolution of brachytherapy for prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 415-439.	1.9	106
203	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017, 71, 618-629.	0.9	2,497
204	Emerging Technologies and Techniques in Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2017, 27, 34-42.	1.0	10
205	Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 822-829.	0.4	50
206	Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 275-285.	0.4	606
207	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
208	Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 128.	1.8	25
209	Current status of brachytherapy in cancer treatment – short overview. <i>Journal of Contemporary Brachytherapy</i> , 2017, 9, 581-589.	0.4	117
210	Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. <i>BMC Cancer</i> , 2017, 17, 573.	1.1	18
211	Brachytherapy: The Original Altered Fractionation. <i>Medical Radiology</i> , 2017, , 65-73.	0.0	0
212	Radiation treatment of prostate cancers – the contemporary role of modern brachytherapy techniques. <i>Journal of Contemporary Brachytherapy</i> , 2017, 5, 391-392.	0.4	1
213	Results of 14 years of brachytherapy for localized prostate cancer in Denmark: the Herlev cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 164-168.	0.6	4
214	Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. <i>BJU International</i> , 2018, 122, 610-617.	1.3	8
215	Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. <i>Cancer Medicine</i> , 2018, 7, 677-689.	1.3	41

#	ARTICLE	IF	CITATIONS
216	Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). Molecular Pathology Library, 2018, , 475-501.	0.1	2
217	Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy. Brachytherapy, 2018, 17, 313-318.	0.2	7
218	Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-caesium: Results of a prospective phase II study. Brachytherapy, 2018, 17, 265-276.	0.2	12
219	Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial. Trials, 2018, 19, 212.	0.7	4
220	Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer. Brachytherapy, 2018, 17, 524-529.	0.2	7
221	Oncentra brachytherapy planning system. Medical Dosimetry, 2018, 43, 141-149.	0.4	5
222	The Evolution of Radiation Therapy in Treating Cancer. Seminars in Oncology Nursing, 2018, 34, 151-157.	0.7	71
223	National trends in management of localized prostate cancer: A population based analysis 2004-2013. Prostate, 2018, 78, 512-520.	1.2	49
224	Long-term oncological outcomes and toxicity in 597 men aged ≥60 years at time of low-dose-rate brachytherapy for localised prostate cancer. BJU International, 2018, 121, 38-45.	1.3	27
225	Comparative Analysis of Clinical Outcomes and Procedural Costs between the Conventional Two-stage Technique and 4D Brachytherapy for Early Prostate Cancer. Clinical Oncology, 2018, 30, 57-64.	0.6	7
226	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. International Journal of Radiation Oncology Biology Physics, 2018, 100, 374-382.	0.4	42
227	Brachytherapy for Prostate Cancer. , 2018, , 87-98.		0
228	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	1.3	22
229	Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1192-1198.	0.8	80
231	Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. Journal of Contemporary Brachytherapy, 2018, 10, 495-502.	0.4	15
232	Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1543-1550.	0.4	9
233	A novel radiation-shielding undergarment using tungsten functional paper for patients with permanent prostate brachytherapy. Journal of Radiation Research, 2018, 59, 333-337.	0.8	15
234	Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. Cancers, 2018, 10, 480.	1.7	24

#	ARTICLE	IF	CITATIONS
235	Using a surgical prostate-specific antigen threshold of >0.2Âng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. <i>Brachytherapy</i> , 2018, 17, 837-844.	0.2	29
236	Number of radiotherapy treatment machines in the population and cancer mortality: an ecological study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1249-1273.	1.5	6
237	Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 297-305.	0.4	12
238	Plan reproducibility of intraoperatively custom-built linked seeds compared to loose seeds for prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 291-296.	0.4	4
239	Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2018, 70, 265-271.	3.4	43
240	Serum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma. <i>Oncology Letters</i> , 2018, 16, 6171-6180.	0.8	2
241	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. <i>Diagnostic and Interventional Radiology</i> , 2018, 24, 46-53.	0.7	21
242	High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer. <i>Cancers</i> , 2018, 10, 322.	1.7	6
243	Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer. <i>Brachytherapy</i> , 2018, 17, 882-887.	0.2	5
244	Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. <i>Oncolmmunology</i> , 2018, 7, e1496881.	2.1	33
247	Evaluation of the "Quadrella" at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy. <i>Brachytherapy</i> , 2018, 17, 782-787.	0.2	2
248	Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental externalAbeam radiation therapy in 2216 patients. <i>Brachytherapy</i> , 2018, 17, 799-807.	0.2	9
249	Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1148-1159.	1.0	21
250	Low dose rate prostate brachytherapy. <i>Translational Andrology and Urology</i> , 2018, 7, 341-356.	0.6	30
251	External Beam Radiotherapy for Advanced Prostate Cancer: Dose, Technique, and Fractionation. , 2018, , 77-83.		0
252	Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer. <i>World Journal of Surgical Oncology</i> , 2018, 16, 107.	0.8	4
253	Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer. <i>American Journal of Roentgenology</i> , 2018, 211, 797-804.	1.0	23
254	UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 238-245.	0.4	7

#	ARTICLE	IF	CITATIONS
255	Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy. , 2018, , 1-14.		0
256	Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. <i>Advances in Radiation Oncology</i> , 2018, 3, 170-180.	0.6	47
257	Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer—A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor—. <i>Brachytherapy</i> , 2018, 17, 537-543.	0.2	8
258	Brachytherapy boost for prostate cancer: A national survey from Groupe curiethÃ©rapie â€“ SociÃ©tÃ© franÃ§aise de radiothÃ©rapie oncologique. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 847-852.	0.6	6
259	Decision Support Systems in Prostate Cancer Treatment: An Overview. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	19
260	Comparative effectiveness of treatments for high-risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 574.e11-574.e18.	0.8	13
261	How might financial pressures have impacted brachytherapy? A proposed narrative to explain the declines in cervical and prostate brachytherapy utilization. <i>Brachytherapy</i> , 2019, 18, 780-786.	0.2	11
262	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 141, 5-13.	0.3	62
263	Quality of life outcomes after low doseâ€rate brachytherapy for localized prostate cancer: Current status and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 1099-1105.	0.5	2
264	Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 320-328.	0.4	8
265	Combined-modality 125J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects. <i>World Journal of Urology</i> , 2019, 37, 2355-2363.	1.2	4
266	Localized prostate cancer with pelvic arteriovenous malformation treated with lowâ€doseâ€rate brachytherapy after transcatheter embolization: Two case reports. <i>IJU Case Reports</i> , 2019, 2, 90-94.	0.1	1
267	Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion imageâ€based post-implant dosimetry of prostate brachytherapy. <i>Journal of Radiation Research</i> , 2019, 60, 483-489.	0.8	2
268	Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells. <i>Oncology Letters</i> , 2019, 17, 5830-5838.	0.8	18
269	Risk-adapted moderate hypofractionation of prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 894-901.	1.0	5
270	Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 288-298.	0.7	2
271	Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification. <i>PLoS ONE</i> , 2019, 14, e0215582.	1.1	7
272	Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions. <i>Advances in Radiation Oncology</i> , 2019, 4, 103-111.	0.6	6

#	ARTICLE	IF	CITATIONS
273	Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. <i>Frontiers in Oncology</i> , 2019, 9, 1273.	1.3	3
274	Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 409-416.	0.4	5
275	A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate. <i>Frontiers in Oncology</i> , 2019, 9, 1378.	1.3	20
276	A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 285-291.	0.6	7
277	Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 14, 51-58.	0.9	12
278	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). <i>British Journal of Radiology</i> , 2019, 92, 20180494.	1.0	50
279	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 552-555.	0.9	43
280	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019, 18, 186-191.	0.2	18
281	Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<math>\leq 60\text{cc}</math>) and large (>math>60\text{cc}</math>) prostate glands. <i>Brachytherapy</i> , 2019, 18, 13-21.	0.2	7
282	Hemiablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer. <i>BJU International</i> , 2020, 125, 383-390.	1.3	11
283	Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. <i>International Journal of Urology</i> , 2020, 27, 17-23.	0.5	17
284	Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 255-266.e7.	0.9	9
285	Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 463-469.	0.3	3
286	Current status of prostate brachytherapy in Japan. <i>Japanese Journal of Radiology</i> , 2020, 38, 934-941.	1.0	2
287	Technical challenges and potential solutions for rectal and sigmoid tumours following previous radiation for prostate malignancy: A case series. <i>International Journal of Surgery Case Reports</i> , 2020, 74, 15-18.	0.2	0
288	Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125 I brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial. <i>International Journal of Urology</i> , 2020, 27, 755-759.	0.5	2
289	Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2020, 19, 574-583.	0.2	13
290	Salvage I-125 brachytherapy for locally-recurrent prostate cancer after radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 754-759.	0.3	3



#	ARTICLE	IF	CITATIONS
291	Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis. <i>Cancers</i> , 2020, 12, 2593.	1.7	26
292	Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results. <i>Advances in Radiation Oncology</i> , 2020, 5, 388-395.	0.6	2
293	Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 6-11.	0.4	8
294	Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1 0.784314 rgBT /Overl	1.0	2
295	Conventional vs machine learning-based treatment planning in prostate brachytherapy: Results of a Phase I randomized controlled trial. <i>Brachytherapy</i> , 2020, 19, 470-476.	0.2	23
296	COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. <i>Brachytherapy</i> , 2020, 19, 401-411.	0.2	32
297	Prostate cancer Monte Carlo dose model with <sup>177</sup> Lutetium and <sup>125</sup> Iodine treatments. <i>Radiation Physics and Chemistry</i> , 2020, 174, 108908.	1.4	4
298	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	0.9	1,545
299	Challenges influencing the utilization of prostate brachytherapy in the United States. <i>Radiotherapy and Oncology</i> , 2021, 154, 123-124.	0.3	2
300	The Case for Brachytherapy: Why It Deserves a Renaissance. <i>Advances in Radiation Oncology</i> , 2021, 6, 100605.	0.6	10
301	High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 245-253.	0.4	8
302	High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-Oncology. <i>Diagnostics</i> , 2021, 11, 400.	1.3	2
303	Knowledge-based inverse treatment planning for low-dose-rate prostate brachytherapy. <i>Medical Physics</i> , 2021, 48, 2108-2117.	1.6	4
304	Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. <i>Journal of Urology</i> , 2021, 205, 1055-1062.	0.2	12
305	<sup>18</sup> F-fluciclovine PET/CT in prostate cancer. <i>Urologie Pro Praxi</i> , 2021, 22, 5-8.	0.0	0
306	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1120-1128.	2.0	10
307	The one hundred most cited publications in prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 611-623.	0.2	1
308	Brachytherapy: A Comprehensive Review. <i>Progress in Medical Physics</i> , 2021, 32, 25-39.	0.5	5

#	ARTICLE	IF	CITATIONS
309	Costâ€“Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 2385-2398.	0.9	2
310	Intraprostatic calcification and biochemical recurrence in men treated with cesium-131 prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 859-865.	0.2	1
311	Comparison of diseaseâ€“specific quality of life in prostate cancer patients treated with lowâ€“doseâ€“rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. <i>International Journal of Urology</i> , 2021, 28, 1171-1176.	0.5	1
312	Multiple direction needle-path planning and inverse dose optimization for robotic low-dose rate brachytherapy. <i>Zeitschrift Fur Medizinische Physik</i> , 2022, 32, 173-187.	0.6	2
314	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 4470.	1.7	6
315	Focal Brachytherapy for Localized Prostate Cancer: Midterm Outcomes. <i>Practical Radiation Oncology</i> , 2021, 11, e477-e485.	1.1	7
316	Prostate Brachytherapy: Low Dose Rate. , 2013, , 719-738.		1
317	Management of Localized and Locally Advanced Prostate Cancer. , 2020, , 579-590.		1
318	Prostate: Low Dose Rate Brachytherapy. <i>Medical Radiology</i> , 2016, , 299-317.	0.0	1
319	Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 91.e7-91.e15.	0.8	11
320	The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 679-684.	0.8	2
321	Obstructive urination problems after high-dose-rate brachytherapy boost treatment for prostate cancer are avoidable. <i>Radiology and Oncology</i> , 2016, 50, 94-103.	0.6	2
322	Prostatectomy Provides Better Symptom-Free Survival Than Radiotherapy Among Patients With High-Risk or Locally Advanced Prostate Cancer After Neoadjuvant Hormonal Therapy. <i>The Korean Journal of Urological Oncology</i> , 2018, 16, 126-134.	0.1	1
323	Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis. <i>Cureus</i> , 2017, 9, e1453.	0.2	4
324	Incidence and Prognostic Factors for Complications After Permanent Interstitial Brachytherapy. , 2013, , 207-213.		0
325	Improved Outcomes for Prostate Cancer Using Hypofractionated Radiotherapy and Dose Escalation to 55Gy. <i>Journal of Nuclear Medicine &amp; Radiation Therapy</i> , 2014, 05, .	0.2	0
326	Aspect post-thÃ©rapeutique du cancer de la prostate. , 2014, , 181-204.		0
327	Grundlagen der Radioonkologie. , 2014, , 223-228.		0

#	ARTICLE	IF	CITATIONS
328	Brachytherapy. , 2015, , 79-96.		0
329	Brachytherapy for Prostate Cancer. , 2015, , 743-772.		0
330	Focal Brachytherapy. , 2015, , 153-162.		0
331	Alternative Verfahren bei Prostatakrebs. , 2016, , 1-63.		0
332	Therapieplanung. , 2017, , 139-159.		0
333	Focal Brachytherapy and Intensity-Modulated Radiation Therapy. Current Clinical Urology, 2017, , 355-371.	0.0	0
334	Advanced Radiotherapy Techniques in Prostate Cancer. , 2017, , 273-291.		0
335	Management of Prostate Cancer. , 2017, , 19-26.		0
336	Brachytherapy guideline in prostate cancer (high and low dose rate). Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2017, 63, 293-298.	0.3	0
339	Prostate Brachytherapy: Clinical Efficacy and Future Trends. , 2019, , 137-146.		0
340	Management of Nonmetastatic Failure Following Local Prostate Cancer Therapy. , 2019, , 227-240.		0
341	Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 5-9.	0.7	0
342	Braquiterapia para el cÃ¡ncer de prÃ³stata. Una revisiÃ³n actualizada de su historia, sus indicaciones, la evidencia que la sustenta y sus controversias.. Ars Medica, 2019, 44, 35-43.	0.1	0
343	Multi-scale tissue architecture analysis of favorable-risk prostate cancer: Correlation with biochemical recurrence. Investigative and Clinical Urology, 2020, 61, 482.	1.0	2
344	High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses â€“ 14 years of single-centre experience. Journal of Contemporary Brachytherapy, 2020, 12, 533-539.	0.4	8
345	Digital Image Analysis in Pathology Using DNA Stain: Contributions in Cancer Diagnostics and Development of Prognostic and Theranostic Biomarkers. Lecture Notes in Computer Science, 2020, , 246-263.	1.0	0
346	Bladder surface dose modeling in prostate cancer radiotherapy: An analysis of motionâ€“induced variations and the cumulative dose across the treatment. Medical Physics, 2021, 48, 8024-8036.	1.6	2
347	Grundlagen der Radioonkologie. , 2014, , 223-228.		0

#	ARTICLE	IF	CITATIONS
348	The Role of MRI in Recurrent Prostate Cancer. , 2021, , 65-73.		0
349	Treatment options for localized prostate cancer. Canadian Family Physician, 2013, 59, 1269-74.	0.1	37
350	MANAGEMENT OF PROSTATE CANCER IN ACCRA, GHANA. Journal of the West African Colleges of Surgeons, 2016, 6, 31-65.	0.0	3
351	A Systems Engineering and Decision-Support Tool to Enhance Care of Veterans Diagnosed With Prostate Cancer. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 57S-60S.	0.6	0
352	Defining Biochemical Cure After Low Dose Rate Prostate Brachytherapy: External Validation of 4-year Prostate-specific Antigen Nadir as a Predictor of 10- and 15-year Disease-free Survival. Clinical Oncology, 2021, , .	0.6	2
353	Prostatakarzinom: Strahlentherapie als kurative Option. , 0, , .		0
354	Local seed displacement from Day 0 to Day 30 in I-125 permanent prostate brachytherapy: A detailed, computed tomography-based analysis. Brachytherapy, 2022, 21, 208-215.	0.2	2
355	Intensity-Modulated Radiotherapy with Regional Hyperthermia for High-Risk Localized Prostate Carcinoma. Cancers, 2022, 14, 400.	1.7	8
356	Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigenâ€“Positron Emission Tomography and Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1126-1134.	0.4	5
357	Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization. Brachytherapy, 2022, 21, 308-316.	0.2	5
358	Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning. Journal of Contemporary Brachytherapy, 2022, 14, 1-6.	0.4	3
359	Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan. Journal of Contemporary Brachytherapy, 2022, 14, 157-168.	0.4	1
360	PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer. Oncogenesis, 2022, 11, 10.	2.1	6
361	Triâ€“modality therapy with iâ€“125 brachytherapy, external beam radiation therapy, and shortâ€“term hormone therapy for highâ€“risk prostate cancer after holmium laser enucleation of the prostate. IJU Case Reports, 0, , .	0.1	1
362	Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy. Brachytherapy, 2022, 21, 424-434.	0.2	5
363	Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labelled, Randomized, Nonâ€“Placebo-Controlled Study. Urology, 2022, 161, 87-92.	0.5	1
364	MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. Clinical Genitourinary Cancer, 2022, , .	0.9	6
365	Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiation Oncology, 2022, 17, 71.	1.2	5

#	ARTICLE	IF	CITATIONS
368	Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 0, , .	0.4	0
369	Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer. <i>Cancers</i> , 2022, 14, 2226.	1.7	4
370	Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2022, , .	0.2	2
371	Relative Incidence of Emergency Department Visits After Treatment for Prostate Cancer with Radiation Therapy or Radical Prostatectomy. <i>Practical Radiation Oncology</i> , 2022, , .	1.1	0
372	Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2022, , .	0.2	0
373	Concordance of MRI-Guided Fusion and Systematic 12-Core Prostate Biopsy for the Detection of Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
374	External beam radiation therapyâ€™treatment factorsâ€™prognostic of biochemical failure free survival: a multi-institutional retrospective study for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	1
375	Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
376	Malignancies in HIV. , 2021, , 313-354.		0
377	Local dose (biologically effective dose $\approx 180\%$ Gy <sup>2</sup> ) is an important predictor of biochemical recurrence in patients undergoing lowâ€™doseâ€™rate brachytherapy. <i>International Journal of Urology</i> , 2022, 29, 1560-1568.	0.5	2
378	A CALL TO ARMS: The Case for MRI-Assisted Radiosurgery (MARS) vs. Stereotactic Body Radiation Therapy or Robotic-Assisted Radical Prostatectomy. <i>Brachytherapy</i> , 2023, 22, 12-14.	0.2	1
379	Successful Salvage Brachytherapy after Infusion of Gold AuroShell Nanoshells for Localized Prostate Cancer in a Human Patient. <i>Advances in Radiation Oncology</i> , 2023, 8, 101202.	0.6	3
380	The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer. <i>Prostate International</i> , 2023, , .	1.2	0
381	Dose Distribution of High Dose-Rate and Low Dose-Rate Prostate Brachytherapy at Different Intervalsâ€™Impact of a Hydrogel Spacer and Prostate Volume. <i>Cancers</i> , 2023, 15, 1396.	1.7	1
382	Quality of life in patients who underwent robotâ€™assisted radical prostatectomy compared with those who underwent lowâ€™doseâ€™rate brachytherapy. <i>Prostate</i> , 2023, 83, 701-712.	1.2	1
383	Health Services Research in Brachytherapy: Current Understanding and Future Challenges. <i>Clinical Oncology</i> , 2023, , .	0.6	1
384	Do dosiomic features extracted from planned 3D dose distribution improve biochemical failure-free survival prediction: an analysis based on a large multi-institutional dataset?. <i>Advances in Radiation Oncology</i> , 2023, , 101227.	0.6	0
385	Focal salvage high-dose-rate brachytherapy with implantable rectum spacer for locally recurrent prostate cancer after initial low-dose-rate with grade 3 rectal toxicity. <i>Journal of Contemporary Brachytherapy</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
386	Seed Density as a New Predictive Index of Seed Migration in Brachytherapy for Prostate Cancer Using Iodine-125 Loose Seed. Current Oncology, 2023, 30, 4060-4066.	0.9	0